MERLIN: Two-Year Results of Brolucizumab in Participants With Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid

Macular DiseasesRetinal Diseases

Persistence of Retinal Fluid after Anti-VEGF treatment for neovascular age-related macular degeneration: A Systematic Review and Meta-Analysis

Ophthalmol Retina

Ting Yap DW, Jyn Tan BK, Yi Chong KT, Wong TY, Gemmy Cheung CM

doi: 10.1016/j.oret.2025.01.010

Macular Diseases

Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration

J Clin Med

Hatz K, Ambresin A, Schmid M, Prünte C, Barthelmes D, Machewitz T, Allmeier H, Somfai GM, XTEND Study Group

doi: 10.3390/jcm14072370

Macular Diseases

TALON Phase IIIb Study: 32 Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age Related Macular Degeneration

Ophthalmol Retina

Regillo C, Kaiser PK, Kertes PJ, Gillies M, Maio-Twofoot T, D'Souza D, Guenther S, Lawrence D, Holz FG

doi: 10.1016/j.oret.2025.05.030

Macular Diseases

Efficacy and safety of brolucizumab every 6 weeks induction therapy for neovascular age-related macular degeneration

Sci Rep

Honda S, Maruyama-Inoue M, Otsuji T, Kyo A, Kobayashi Y, Yamamoto Y, Gomi F

doi: 10.1038/s41598-025-89638-1

Macular Diseases

Vision-related quality of life impact of age-related macular degeneration in older adults aged 60-100 years: a cross-sectional study

Br J Ophthalmol

Vu TA, Fenwick EK, Man REK, Thakur S, Tan ACS, Cheung CMG, Gupta P, Lamoureux EL

doi: 10.1136/bjo-2024-325713

Macular Diseases

Impact of Duration of Exposure to Intraretinal Fluid on Visual Outcomes in Neovascular Age-Related Macular Degeneration

Ophthalmol Retina

Steinle NC, McCullough AJ, Silva FQ, Du W, Moini H, Singh RP

doi: 10.1016/j.oret.2024.12.018

Macular Diseases

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Ophthalmol Ther

Cancian G, Paris A, Agliati L, Rizzato A, Clerici M, Volpe G, Menghini M, Grimaldi G

doi: 10.1007/s40123-024-01036-4

Macular DiseasesRetinal Diseases

Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study

Eye (Lond)

Puzo M, Calvo-Perez P, Bartol-Puyal F, Sanchez-Monroy J, Martin-Pinardel R, Parrado-Carrillo A, Moll-Udina A, Bernal-Morales C, Sanchez-Vela L, Sararols-Ramsay L, Garay-Aramburu G, Arruabarrena C, García-Arumí J, Abraldes M, Ruiz-Moreno JM, Valldeperas X, Velázquez-Villoria D, Escobar-Barranco JJ, Gallego-Pinazo R, Figueroa MS, Figueras-Roca M, Barthelmes D, Gillies MC, Casaroli-Marano RP, Zarranz-Ventura J, from the writing committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group

doi: 10.1038/s41433-024-03322-8

Macular Diseases

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Clin Exp Ophthalmol

Spooner K, Broadhead G, Fraser-Bell S, Hong T, Wong JG, Chang AA

doi: 10.1111/ceo.14559

Related content

Persistence of Retinal Fluid after Anti-VEGF treatment for neovascular age-related macular degeneration: A Systematic Review and Meta-Analysis

Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration

TALON Phase IIIb Study: 32 Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age Related Macular Degeneration

Efficacy and safety of brolucizumab every 6 weeks induction therapy for neovascular age-related macular degeneration

Vision-related quality of life impact of age-related macular degeneration in older adults aged 60-100 years: a cross-sectional study

Impact of Duration of Exposure to Intraretinal Fluid on Visual Outcomes in Neovascular Age-Related Macular Degeneration

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis